University of Pittsburgh, Abbott Labs to Develop Ras Inhibitors
PITTSBURGH--The University of Pittsburgh, through the researchof investigators Saïd Sebti, PhD, and Andrew Hamilton, PhD,has entered into a research agreement with Abbott Laboratoriesto develop novel cancer drugs that block the activity of the rasoncogene.
PITTSBURGH--The University of Pittsburgh, through the researchof investigators Saïd Sebti, PhD, and Andrew Hamilton, PhD,has entered into a research agreement with Abbott Laboratoriesto develop novel cancer drugs that block the activity of the rasoncogene.
Articles in this issue
Princess Diana Helps Raise Over $1 Million for Cancer Research
Study Gives Terminal Patients Option: $18,000 or More Treatment
Proven: Colorectal Screening Cuts Deaths 50%
Virtual Colonoscopy Technique Feasible in Detecting Polyps
Trimetrexate Appears Beneficial in Colorectal Cancer
FDA Liaison Program Answers Patients' Questions About Trials
New Company Joins With RPR To Develop Intrabody Technology
More Insurers Covering ABMT, Despite Lack of Efficacy Data
Klausner Requests Funds for Five Important 'Investment Opportunities' in Cancer Research
CDC Says Teen Smoking Still Rising
ThinPrep Pap Test Offers Improved Slide Preparation
Taxotere for Anthracycline Refractory Advanced Breast Cancer
ODAC Recommends Approval of Aredia for Breast Cancer Bone Mets
Hycamtin Approved For Ovarian Cancer
Gemzar for Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Recent Videos
Related Content
